TGFB1 and osteogenesis imperfecta: In a phase 1 clinical trial, administration of the human anti-TGFβ antibody fresolimumab at a single dose of either 1 mg or 4 mg to eight adults with moderate or severe OI was well tolerated but had variable effects on bone mass according to OI type, with type IV (moderate OI) patients showing increased LSaBMD; those with type III and VIII (severe OI) did not show such changes (Song et al., 2022).